The candidate, being developed in collaboration with the University of Washington School of Medicine at St Louis (WashU), is a single-dose vaccine that is slated to be a gamechanger for Covid-19 vaccination rollouts. The company has said its administration would require only two drops each in each nostril.
Sources said the company expects the trials to start by early February and has proposed phase I trials on around 375 volunteers. This is similar to Covaxin phase I trials, but at a smaller number of sites – five to six instead of the 11 involved in Covaxin.
Bharat Biotech told TOI that for BBV154 “pre-clinical testing